🌍 MBBS · subject
MBBS Pharmacology Syllabus
The Pharmacology syllabus for MBBS in full: 8 chapters, 33 topics and 78 sub-topics, every one listed below, plus 51 Pharmacology flashcards with answers.
Pharmacology syllabus: all 8 chapters
Expand any chapter to see its topics and sub-topics.
-
General Pharmacology
5 topics- Introduction to pharmacology
- Definitions
- Scope
- Branches of pharmacology
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Excretion of drugs
- Pharmacodynamics
- Mechanisms of drug action
- Drug-receptor interactions
- Dose-response relationships
- Drug potency
- Pharmacogenetics and personalized medicine
- Genetic variation in drug response
- Pharmacogenomic testing
- Implications for drug therapy
- Drug development and regulation
- Preclinical studies
- Clinical trials
- Drug approval process
- Drug scheduling
- Introduction to pharmacology
-
Autonomic Nervous System Pharmacology
4 topics- Introduction to autonomic pharmacology
- Neurotransmitters and receptors in the autonomic nervous system
- Cholinergic drugs
- Agonists
- Antagonists
- Cholinesterase inhibitors
- Adrenergic drugs
- Agonists
- Antagonists
- Adrenergic neuron blockers
- Ganglionic and neuromuscular blocking drugs
- Mechanism of action
- Uses
- Adverse effects
- Introduction to autonomic pharmacology
-
Central Nervous System Pharmacology
7 topics- Introduction to CNS Pharmacology
- Blood-brain barrier
- Neurotransmitters in the CNS
- Receptors in the CNS
- Sedative-hypnotic Drugs
- Benzodiazepines
- Barbiturates
- Non-benzodiazepine sedative-hypnotics
- Antiepileptic Drugs
- Mechanisms of action
- Classification
- Therapeutic uses
- Antipsychotic Drugs
- Typical antipsychotics
- Atypical antipsychotics
- Dopamine receptor antagonists
- Serotonin-dopamine antagonists
- Antidepressant Drugs
- SSRIs
- TCAs
- MAOIs
- Atypical antidepressants
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Analgesic and Anti-inflammatory Drugs
- NSAIDs
- Opioids
- Adjuvant analgesics
- Anxiolytic Drugs
- Benzodiazepines
- Buspirone
- Selective serotonin reuptake inhibitors (SSRIs)
- Introduction to CNS Pharmacology
-
Introduction to cardiovascular pharmacology
3 topics- Hemodynamics
- Cardiac electrophysiology
- Regulation of blood pressure
-
Endocrine Pharmacology
5 topics- Introduction to Endocrine Pharmacology
- Hormone replacement therapy
- Hormone antagonists
- Hormone synthesis inhibitors
- Thyroid and Antithyroid Drugs
- Thyroid hormones
- Antithyroid drugs
- Iodine preparations
- Glucocorticoids and Mineralocorticoids
- Mechanism of action
- Therapeutic uses
- Adverse effects
- Insulin and Oral Hypoglycemic Agents
- Mechanism of action
- Classification
- Therapeutic uses
- Gonadal Hormones and Contraceptives
- Estrogens
- Progestins
- Androgen receptor antagonists
- Contraceptive methods
- Introduction to Endocrine Pharmacology
-
Introduction to chemotherapy
3 topics- Principles of antimicrobial therapy
- Mechanisms of antimicrobial action
- Drug resistance
-
Chemotherapy of Neoplastic Diseases
3 topics- Introduction to cancer chemotherapy
- Principles of cancer therapy
- Cell cycle-specific vs. cell cycle-nonspecific drugs
- Anticancer drugs
- Alkylating agents
- Antimetabolites
- Antitumor antibiotics
- Mitotic inhibitors
- Targeted therapies
- Hormonal therapy
- Hormone receptor antagonists
- Aromatase inhibitors
- Gonadotropin-releasing hormone analogs
- Introduction to cancer chemotherapy
-
Principles of toxicology
3 topics- Mechanisms of toxicity
- Factors affecting toxicity
- Toxicokinetics
MBBS Pharmacology flashcards — 51 questions with answers
Define pharmacology and distinguish its two main branches, pharmacokinetics and pharmacodynamics.
Pharmacology is the science of how drugs interact with living systems. Pharmacokinetics describes what the body does to the drug (absorption, distribution, metabolism, excretion), while pharmacodynamics describes what the drug does to the body (mechanism of action and effects).
What is the difference between a drug's potency and its efficacy?
Potency is the amount of drug needed to produce a given effect (lower $EC_{50}$ = more potent), reflecting position on the dose axis. Efficacy ($E_{max}$) is the maximal effect a drug can produce regardless of dose. A drug can be highly potent but have low efficacy.
State the four pharmacokinetic processes summarized by the acronym ADME.
Absorption (drug entry into the bloodstream), Distribution (transfer to tissues), Metabolism (biotransformation, mainly hepatic), and Excretion (elimination, mainly renal).
Define bioavailability ($F$) and give its value for an intravenous drug.
Bioavailability is the fraction of an administered dose reaching the systemic circulation unchanged. $F = \frac{AUC_{oral}}{AUC_{IV}} \times \frac{Dose_{IV}}{Dose_{oral}}$. For an IV drug $F = 1$ (100%) by definition.
Write the formula for apparent volume of distribution ($V_d$) and explain what a large $V_d$ implies.
$$V_d = \frac{\text{Amount of drug in body}}{\text{Plasma drug concentration}}$$ A large $V_d$ implies extensive tissue distribution (e.g., lipophilic drugs), with relatively little drug remaining in plasma.
Give the relationship between clearance ($CL$), volume of distribution ($V_d$), and elimination half-life ($t_{1/2}$).
$$t_{1/2} = \frac{0.693 \times V_d}{CL}$$ Half-life increases with larger $V_d$ and decreases with greater clearance.
What distinguishes first-order from zero-order elimination kinetics?
In first-order kinetics a constant fraction of drug is eliminated per unit time (rate proportional to concentration; constant $t_{1/2}$). In zero-order kinetics a constant amount is eliminated per unit time because enzymes are saturated (e.g., ethanol, phenytoin, aspirin at high doses).
How many half-lives are required to reach steady state, and what fraction of steady state is achieved at each?
Steady state is essentially reached in about 4-5 half-lives. After 1 $t_{1/2}$ = 50%, 2 = 75%, 3 = 87.5%, 4 = 93.75%, 5 = ~97% of steady-state concentration.
Write the equation for maintenance dose rate at steady state in terms of clearance and target concentration.
$$\text{Maintenance dose rate} = \frac{CL \times C_{ss} \times \tau}{F}$$ where $C_{ss}$ is target steady-state concentration, $\tau$ the dosing interval, and $F$ bioavailability.
Write the loading dose equation and explain why it is independent of clearance.
$$\text{Loading dose} = \frac{V_d \times C_{target}}{F}$$ It depends only on volume of distribution because its goal is to fill the distribution volume to the target concentration immediately, not to balance elimination.
Distinguish Phase I from Phase II drug metabolism reactions.
Phase I reactions (oxidation, reduction, hydrolysis; largely cytochrome P450) introduce or unmask functional groups, often making drugs more polar or active/toxic. Phase II reactions are conjugations (glucuronidation, sulfation, acetylation, glutathione) that add endogenous groups to increase water solubility for excretion.
What is first-pass metabolism and how can it be avoided?
First-pass metabolism is presystemic elimination of an orally absorbed drug by the gut wall and liver before reaching systemic circulation, reducing bioavailability. It is bypassed by sublingual, rectal, transdermal, inhalational, or parenteral routes.
Define therapeutic index (TI) and write its formula.
The therapeutic index is a measure of drug safety: $$TI = \frac{TD_{50}}{ED_{50}}$$ (or $\frac{LD_{50}}{ED_{50}}$ in animals). A larger TI indicates a wider safety margin.
What is pharmacogenetics, and give a classic example of a polymorphism affecting drug metabolism.
Pharmacogenetics studies how individual genetic variation influences drug response. Example: polymorphisms in N-acetyltransferase (NAT2) classify patients as slow or fast acetylators of isoniazid; slow acetylators are prone to peripheral neuropathy.
How do CYP2D6 polymorphisms affect codeine analgesia?
Codeine is a prodrug bioactivated to morphine by CYP2D6. Poor metabolizers get little analgesia, while ultrarapid metabolizers produce excess morphine and risk respiratory depression (especially in children/breastfeeding).
List the phases of clinical drug development (Phase I-IV) and their primary aims.
Phase I: small number of healthy volunteers, assesses safety/pharmacokinetics. Phase II: patients, assesses efficacy and dose-finding. Phase III: large randomized controlled trials confirming efficacy and monitoring adverse effects. Phase IV: post-marketing surveillance for rare/long-term effects.
Define an orphan drug and a black box warning in drug regulation.
An orphan drug is one developed to treat a rare disease, granted regulatory incentives. A black box (boxed) warning is the strictest FDA label warning, highlighting serious or life-threatening risks.
Compare an agonist, a competitive antagonist, and a non-competitive antagonist in terms of their effect on the dose-response curve.
An agonist binds and activates a receptor (produces $E_{max}$). A competitive antagonist shifts the agonist curve rightward (increased $EC_{50}$) with unchanged $E_{max}$ (surmountable). A non-competitive antagonist reduces $E_{max}$ (insurmountable) and may not shift $EC_{50}$.
What is a partial agonist, and how does it behave in the presence of a full agonist?
A partial agonist binds a receptor but produces a submaximal response even at full occupancy (lower intrinsic efficacy). In the presence of a full agonist it acts as a competitive antagonist, lowering the overall response toward its own ceiling.
Define an inverse agonist.
An inverse agonist binds the same receptor as an agonist but stabilizes the inactive conformation, producing an effect opposite to the agonist by reducing constitutive (basal) receptor activity.
Show the other 31 Pharmacology flashcards
Differentiate the two divisions of the autonomic nervous system by their primary neurotransmitters and dominant effects.
The sympathetic ('fight or flight') division releases noradrenaline at most target organs (acetylcholine at sweat glands/ganglia). The parasympathetic ('rest and digest') division releases acetylcholine. They generally exert opposing effects to maintain homeostasis.
Identify the neurotransmitter and receptor type at each location: autonomic ganglia, parasympathetic effector, sympathetic effector (most), and the skeletal neuromuscular junction.
Autonomic ganglia: ACh on nicotinic ($N_N$). Parasympathetic effector: ACh on muscarinic. Most sympathetic effectors: noradrenaline on adrenergic ($\alpha/\beta$). Neuromuscular junction: ACh on nicotinic ($N_M$).
Contrast the second-messenger pathways of the muscarinic receptor subtypes $M_1/M_3/M_5$ versus $M_2/M_4$.
$M_1, M_3, M_5$ couple to $G_q$, activating phospholipase C to raise $IP_3$ and $DAG$ (excitatory, smooth muscle/glandular). $M_2, M_4$ couple to $G_i$, inhibiting adenylyl cyclase and lowering cAMP (cardiac slowing).
Describe the mechanism and key clinical use of physostigmine versus neostigmine.
Both are reversible acetylcholinesterase inhibitors that increase synaptic ACh. Physostigmine is a tertiary amine that crosses the blood-brain barrier (used for anticholinergic/atropine toxicity). Neostigmine is a quaternary amine that does not enter the CNS (used for myasthenia gravis and reversal of non-depolarizing blockade).
What is the mechanism of organophosphate poisoning and its specific antidote?
Organophosphates irreversibly inhibit acetylcholinesterase, causing ACh accumulation and a cholinergic crisis (DUMBBELLS/SLUDGE). Treatment: atropine (blocks muscarinic effects) plus pralidoxime (reactivates cholinesterase before 'aging').
List the classic muscarinic (parasympathetic) effects summarized by the mnemonic DUMBBELS.
Diarrhea, Urination, Miosis, Bradycardia/Bronchospasm, Emesis, Lacrimation, Salivation/Sweating — the signs of muscarinic excess (cholinergic crisis).
Describe atropine's mechanism and its main clinical effects.
Atropine is a competitive muscarinic antagonist. Effects: tachycardia, mydriasis with cycloplegia, dry mouth, decreased secretions, bronchodilation, and reduced GI/bladder motility. Used for bradycardia, as an antisecretory agent, and in organophosphate poisoning.
Match adrenergic receptor subtypes $\alpha_1$, $\alpha_2$, $\beta_1$, $\beta_2$ to their principal effects.
$\alpha_1$: vasoconstriction, mydriasis, sphincter contraction. $\alpha_2$: presynaptic inhibition of NA release, decreased central sympathetic outflow. $\beta_1$: increased heart rate, contractility, and renin release. $\beta_2$: bronchodilation, vasodilation, uterine relaxation, glycogenolysis.
Compare the cardiovascular effects of adrenaline (epinephrine) at low versus high doses.
At low doses $\beta_2$ vasodilation predominates, lowering diastolic pressure and total peripheral resistance. At high doses $\alpha_1$ vasoconstriction dominates, raising systolic and diastolic pressure. $\beta_1$ effects raise heart rate and contractility throughout.
Explain the mechanism of action of beta-blockers and a key contraindication.
Beta-blockers competitively antagonize $\beta$-adrenergic receptors, reducing heart rate, contractility, AV conduction, and renin release, thereby lowering blood pressure and cardiac workload. Non-selective agents are contraindicated in asthma (risk of $\beta_2$-mediated bronchospasm).
How does prazosin lower blood pressure, and what notable adverse effect does it cause?
Prazosin is a selective $\alpha_1$-antagonist that causes arterial and venous dilation, reducing peripheral resistance. It can produce a 'first-dose' orthostatic hypotension/syncope.
Contrast the mechanisms of depolarizing and non-depolarizing neuromuscular blockers.
Depolarizing blockers (succinylcholine) are nicotinic agonists that persistently depolarize the motor end-plate, causing initial fasciculations then flaccid paralysis (Phase I, not reversed by anticholinesterases). Non-depolarizing blockers (e.g., vecuronium, rocuronium) are competitive $N_M$ antagonists causing flaccid paralysis reversible by anticholinesterases.
What is the mechanism of ganglionic blockers, and name a prototype.
Ganglionic blockers (e.g., hexamethonium, trimethaphan) competitively block nicotinic ($N_N$) receptors at autonomic ganglia, interrupting both sympathetic and parasympathetic transmission; net effect depends on the dominant autonomic tone at each organ.
List the major inhibitory and excitatory neurotransmitters of the CNS.
Principal inhibitory neurotransmitters: GABA and glycine. Principal excitatory neurotransmitter: glutamate (acting on NMDA, AMPA, kainate, and metabotropic receptors). Modulatory systems include dopamine, serotonin, noradrenaline, and acetylcholine.
Describe how benzodiazepines and barbiturates differently potentiate the $GABA_A$ receptor.
Both enhance $GABA_A$ chloride channel activity. Benzodiazepines increase the frequency of channel opening (require GABA present). Barbiturates increase the duration of channel opening and at high doses directly open the channel, accounting for their lower margin of safety.
What is the antidote for benzodiazepine overdose and its mechanism?
Flumazenil, a competitive antagonist at the benzodiazepine binding site of the $GABA_A$ receptor. Use cautiously, as it can precipitate seizures in chronically dependent patients.
Compare the sedative-hypnotic safety profiles of benzodiazepines versus barbiturates.
Benzodiazepines have a ceiling effect on CNS depression (rarely fatal alone) and a wide therapeutic index. Barbiturates lack a ceiling, directly opening Cl$^-$ channels, causing dose-dependent respiratory depression and a narrow therapeutic index, making overdose lethal.
Name three principal mechanisms by which antiepileptic drugs reduce neuronal excitability.
1) Blockade of voltage-gated sodium channels (phenytoin, carbamazepine, lamotrigine). 2) Enhancement of GABAergic inhibition (benzodiazepines, valproate, vigabatrin). 3) Blockade of T-type calcium channels (ethosuximide for absence seizures).
Which antiepileptic is first-line for absence seizures, and what is its mechanism?
Ethosuximide is first-line for absence (petit mal) seizures; it blocks T-type calcium channels in thalamic neurons. Valproate is an alternative, especially with coexisting generalized tonic-clonic seizures.
State two serious adverse effects of valproate and one important drug-interaction property.
Valproate can cause hepatotoxicity and neural tube defects (teratogenic, e.g., spina bifida). It is a broad enzyme inhibitor, raising levels of co-administered drugs such as lamotrigine and phenobarbital.
What is the dopamine hypothesis of schizophrenia and how do typical antipsychotics act on it?
The dopamine hypothesis attributes positive symptoms to excess dopaminergic activity in the mesolimbic pathway. Typical (first-generation) antipsychotics block $D_2$ receptors, relieving positive symptoms but causing extrapyramidal effects from nigrostriatal $D_2$ blockade.
Distinguish typical from atypical antipsychotics regarding receptor profile and side effects.
Typical antipsychotics are potent $D_2$ antagonists with high extrapyramidal symptom (EPS) and hyperprolactinemia risk. Atypicals block $D_2$ and $5\text{-}HT_{2A}$ receptors, causing fewer EPS but more metabolic side effects (weight gain, diabetes, dyslipidemia).
What is neuroleptic malignant syndrome and its key features?
A life-threatening idiosyncratic reaction to antipsychotics (dopamine blockade) marked by hyperthermia, severe muscle rigidity ('lead-pipe'), autonomic instability, altered mental status, and elevated creatine kinase. Treated by stopping the drug plus dantrolene and/or bromocriptine.
Compare the mechanisms of SSRIs, TCAs, and MAOIs as antidepressants.
SSRIs selectively block serotonin reuptake. TCAs block reuptake of both serotonin and noradrenaline (and block muscarinic, histaminergic, $\alpha_1$ receptors, causing more side effects). MAOIs inhibit monoamine oxidase, reducing breakdown of serotonin, noradrenaline, and dopamine.
Why must MAOIs be used with dietary caution, and what is serotonin syndrome?
MAOIs combined with tyramine-rich foods cause a hypertensive crisis (the 'cheese reaction'). Serotonin syndrome is excess serotonergic activity (e.g., SSRI + MAOI) causing the triad of altered mental status, autonomic hyperactivity, and neuromuscular abnormalities (clonus, hyperreflexia).
Describe the mechanism of action of NSAIDs and distinguish COX-1 from COX-2.
NSAIDs inhibit cyclooxygenase, reducing prostaglandin synthesis (analgesia, antipyresis, anti-inflammation). COX-1 is constitutive (gastric protection, platelet thromboxane, renal flow); COX-2 is inducible at inflammation sites. Selective COX-2 inhibitors spare the stomach but raise cardiovascular risk.
How does aspirin's effect on platelets differ from that of other NSAIDs?
Aspirin irreversibly acetylates COX-1, permanently inhibiting platelet thromboxane $A_2$ synthesis for the platelet's ~7-10 day lifespan. Other NSAIDs cause reversible, competitive COX inhibition lasting only while drug is present.
Explain the analgesic mechanism of opioids and three classic adverse effects.
Opioids agonize $\mu$ (and $\kappa$, $\delta$) receptors, $G_i$-coupled, reducing cAMP, decreasing neurotransmitter release and hyperpolarizing neurons to inhibit pain transmission. Classic adverse effects: respiratory depression, constipation, and miosis (with tolerance and dependence).
Why is buspirone preferred over benzodiazepines for chronic generalized anxiety, and what is its mechanism?
Buspirone is a $5\text{-}HT_{1A}$ partial agonist that relieves anxiety without sedation, dependence, or potentiation of alcohol. Its drawback is delayed onset (1-2 weeks), unlike the immediate but dependence-prone benzodiazepines.
Write the equation for mean arterial pressure (MAP) in terms of cardiac output and resistance, and in terms of systolic/diastolic pressures.
$$MAP = CO \times SVR \quad\text{and}\quad MAP \approx DBP + \frac{1}{3}(SBP - DBP)$$ where $CO$ is cardiac output, $SVR$ systemic vascular resistance, $SBP$ systolic and $DBP$ diastolic pressure (pulse pressure $= SBP - DBP$).
Name the five phases (0-4) of the ventricular cardiac action potential and the ion movement in each.
Phase 0: rapid depolarization (fast $\ce{Na+}$ influx). Phase 1: early repolarization ($\ce{K+}$ efflux, $\ce{Na+}$ channels close). Phase 2: plateau ($\ce{Ca^2+}$ influx balances $\ce{K+}$ efflux). Phase 3: repolarization ($\ce{K+}$ efflux). Phase 4: resting potential maintained by $\ce{Na+/K+}$-ATPase (spontaneous depolarization in pacemaker cells).
Same Pharmacology syllabus in other exams
The Pharmacology outline above is identical in these 3 exams:
MBBS Pharmacology FAQ
What is in the MBBS Pharmacology syllabus?
MBBS Pharmacology is split into 8 chapters: General Pharmacology, Autonomic Nervous System Pharmacology, Central Nervous System Pharmacology, Introduction to cardiovascular pharmacology, Endocrine Pharmacology, Introduction to chemotherapy, Chemotherapy of Neoplastic Diseases and Principles of toxicology. Together they contain 33 topics and 78 sub-topics.
How many chapters are in MBBS Pharmacology?
8 chapters, containing 33 topics and 78 sub-topics. The largest chapter is Central Nervous System Pharmacology, with 7 topics.
Are there flashcards for MBBS Pharmacology?
Yes — a 51-card Pharmacology deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.